文献速递肾移植急性肾损伤

deceased供者急性肾损伤与肾移植受者急性排斥反应:多中心队列研究

Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort.
PubMed 文献 · Am J Kidney Dis · 2022-10-01

该前瞻性多中心队列纳入862例 deceased 供者和1137例肾移植受者,检测供者尿IL-18、KIM-1和NGAL,并按AKIN标准评估供者临床AKI,随访移植后第一年。结果显示供者尿生物标志物与活检证实的急性排斥反应(BPAR)及移植物衰竭复合终点无显著关联,临床定义AKI与主要结局及包含新生DSA的次要结局亦无显著关联。

要点

  • 供者尿IL-18、KIM-1、NGAL最高三分位与最低三分位相比,主要结局风险无显著差异。
  • 供者临床AKI与BPAR及移植物衰竭复合终点无显著关联。
  • 供者损伤生物标志物与包含新生DSA的次要复合终点亦无显著关联。

核心结论

  • 在几乎均接受 thymoglobulin 诱导的大规模肾移植受者队列中,供者损伤生物标志物与移植物衰竭和排斥反应无关,也与包含新生DSA的次要结局无关。
  • 这些发现提供了一定 reassurance,即中心可以成功管理使用 deceased 供者AKI肾脏的免疫学并发症。

研究设计与样本

  • 前瞻性队列研究,纳入13个中心的862例 deceased 供者和对应的1137例肾移植受者。
  • 检测供者尿IL-18、KIM-1和NGAL浓度,并用AKIN标准评估供者临床AKI。
  • 主要结局为BPAR和移植物衰竭(非死亡所致)的复合终点,次要结局为BPAR、移植物衰竭和/或新生DSA的复合终点,均在移植后第一年 ascertain。
  • 采用以死亡为竞争风险的多变量Fine-Gray模型分析。

主要发现

  • 受者平均年龄54±13(SD)岁,82%接受抗胸腺细胞球蛋白诱导。
  • 供者尿IL-18最高三分位 vs 最低三分位与主要结局的亚分布HR为0.76(95%CI 0.45-1.28),无显著关联。
  • 供者尿KIM-1最高三分位 vs 最低三分位与主要结局的亚分布HR为1.20(95%CI 0.69-2.07),无显著关联。
  • 供者尿NGAL最高三分位 vs 最低三分位与主要结局的亚分布HR为1.14(95%CI 0.71-1.84),无显著关联。
  • 临床定义AKI与主要结局无显著关联,供者生物标志物与BPAR、移植物衰竭和/或新生DSA复合结局亦无显著关联。

关键数值与推荐

  • 主要结局为BPAR和移植物衰竭(非死亡所致)的复合终点。
  • 次要结局为BPAR、移植物衰竭和/或新生DSA的复合终点。
  • 供者临床AKI按AKIN标准评估。

临床怎么用

  • 原文结论未给出具体临床推荐。

局限性

  • BPAR通过原因性活检而非监测性活检 ascertain。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Donor acute kidney injury (AKI) activates innate immunity, enhances HLA expression in the kidney allograft, and provokes recipient alloimmune responses. We hypothesized that injury and inflammation that manifested in deceased-donor urine biomarkers would be associated with higher rates of biopsy-proven acute rejection (BPAR) and allograft failure after transplantation. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: 862 deceased donors for 1,137 kidney recipients at 13 centers. EXPOSURES: We measured concentrations of interleukin 18 (IL-18), kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) in deceased donor urine. We also used the Acute Kidney Injury Network (AKIN) criteria to assess donor clinical AKI. OUTCOMES: The primary outcome was a composite of BPAR and graft failure (not from death). A secondary outcome was the composite of BPAR, graft failure, and/or de novo donor-specific antibody (DSA). Outcomes were ascertained in the first posttransplant year. ANALYTICAL APPROACH: Multivariable Fine-Gray models with death as a competing risk. RESULTS: Mean recipient age was 54 ± 13 (SD) years, and 82% received antithymocyte globulin. We found no significant associations between donor urinary IL-18, KIM-1, and NGAL and the primary outcome (subdistribution hazard ratio [HR] for highest vs lowest tertile of 0.76 [95% CI, 0.45-1.28], 1.20 [95% CI, 0.69-2.07], and 1.14 [95% CI, 0.71-1.84], respectively). In secondary analyses, we detected no significant associations between clinically defined AKI and the primary outcome or between donor biomarkers and the composite outcome of BPAR, graft failure, and/or de novo DSA. LIMITATIONS: BPAR was ascertained through for-cause biopsies, not surveillance biopsies. CONCLUSIONS: In a large cohort of kidney recipients who almost all received induction with thymoglobulin, donor injury biomarkers were associated with neither graft failure and rejection nor a secondary outcome that included de novo DSA. These findings provide some reassurance that centers can successfully manage immunological complications using deceased-donor kidneys with AKI.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Reese PP, Doshi MD, Hall IE, et al. Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort. Am J Kidney Dis. 2022. PMID: 36191727. doi:10.1053/j.ajkd.2022.08.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。